Annexon Biosciences (ANNX) Stock Forecast & Price Target

Compare

1,252 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ANNX Analyst Ratings

Strong Buy

6 Buy

0 Hold

0 Sell

Based on 6 analysts giving stock ratings to

Annexon

Biosciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ANNX Stock 12 Month Forecast

Average Price Target

$11.60

▲(449.76% Upside)

Based on 6 Wall Street analysts offering 12 month price targets for Annexon Biosciences in the last 3 months. The average price target is $11.60 with a high forecast of $14.00 and a low forecast of $9.00. The average price target represents a 449.76% change from the last price of $2.11.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","15":"$15","3.75":"$3.75","7.5":"$7.5","11.25":"$11.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$14.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$11.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$9.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.75,7.5,11.25,15],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Dec<br/>2024","9":"Apr<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.45,3.3384615384615386,4.226923076923077,5.115384615384616,6.003846153846155,6.892307692307693,7.7807692307692315,8.669230769230769,9.557692307692308,10.446153846153848,11.334615384615386,12.223076923076924,13.111538461538462,{"y":14,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.45,3.153846153846154,3.8576923076923078,4.561538461538461,5.265384615384615,5.969230769230769,6.6730769230769225,7.3769230769230765,8.080769230769231,8.784615384615385,9.48846153846154,10.192307692307692,10.896153846153844,{"y":11.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.45,2.953846153846154,3.457692307692308,3.9615384615384617,4.4653846153846155,4.969230769230769,5.473076923076923,5.976923076923077,6.480769230769231,6.984615384615385,7.4884615384615385,7.992307692307692,8.496153846153845,{"y":9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.63,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.75,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.83,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.1,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.11,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.28,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.27,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.13,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.64,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.81,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.86,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.47,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.45,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$14.00

Average Price Target$11.60

Lowest Price Target$9.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Derek Archila

Wells Fargo

$14

Buy

563.51%

Upside

Reiterated

08/15/25

Annexon Biosciences (ANNX) Receives a Buy from Wells Fargo

Joseph Stringer

Needham

$11

Buy

421.33%

Upside

Reiterated

08/15/25

Promising Outlook for Annexon Biosciences: Buy Rating Backed by Strong Pipeline and Financial Stability

Andrew Tsai

Jefferies

$10

Buy

373.93%

Upside

Reiterated

08/15/25

Jefferies Keeps Their Buy Rating on Annexon Biosciences (ANNX)

Ananda Ghosh

H.C. Wainwright

$14

Buy

563.51%

Upside

Reiterated

08/15/25

Analysts Offer Insights on Healthcare Companies: Protara Therapeutics (NASDAQ: TARA), Annexon Biosciences (NASDAQ: ANNX) and Agilent (NYSE: A)

Phil Nadeau

TD Cowen

―

Buy

―

Reiterated

08/14/25

TD Cowen Keeps Their Buy Rating on Annexon Biosciences (ANNX)

Tazeen Ahmad

Bank of America Securities

Buy

326.54%

Upside

Reiterated

08/14/25

Bank of America Securities Sticks to Their Buy Rating for Annexon Biosciences (ANNX)

Pete Stavropoulos

Cantor Fitzgerald

―

Buy

―

Reiterated

05/13/25

Cantor Fitzgerald reiterates Overweight Rating on Annexon Biosciences (ANNX)Cantor Fitzgerald analyst Pete Stavropoulos reiterated an Overweight rating on Annexon Biosciences (NASDAQ: ANNX).

Dex Genotek

TR | OpenAI - 4o

―

Sell

―

Reiterated

04/22/25

AI Generated ArticleAI Generated Article

Anupam Rama

J.P. Morgan

―

Buy

―

Reiterated

03/03/25

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Derek Archila

Wells Fargo

$14

Buy

563.51%

Upside

Reiterated

08/15/25

Annexon Biosciences (ANNX) Receives a Buy from Wells Fargo

Joseph Stringer

Needham

$11

Buy

421.33%

Upside

Reiterated

08/15/25

Promising Outlook for Annexon Biosciences: Buy Rating Backed by Strong Pipeline and Financial Stability

Andrew Tsai

Jefferies

$10

Buy

373.93%

Upside

Reiterated

08/15/25

Jefferies Keeps Their Buy Rating on Annexon Biosciences (ANNX)

Ananda Ghosh

H.C. Wainwright

$14

Buy

563.51%

Upside

Reiterated

08/15/25

Analysts Offer Insights on Healthcare Companies: Protara Therapeutics (NASDAQ: TARA), Annexon Biosciences (NASDAQ: ANNX) and Agilent (NYSE: A)

Phil Nadeau

TD Cowen

―

Buy

―

Reiterated

08/14/25

TD Cowen Keeps Their Buy Rating on Annexon Biosciences (ANNX)

Tazeen Ahmad

Bank of America Securities

Buy

326.54%

Upside

Reiterated

08/14/25

Bank of America Securities Sticks to Their Buy Rating for Annexon Biosciences (ANNX)

Pete Stavropoulos

Cantor Fitzgerald

―

Buy

―

Reiterated

05/13/25

Cantor Fitzgerald reiterates Overweight Rating on Annexon Biosciences (ANNX)Cantor Fitzgerald analyst Pete Stavropoulos reiterated an Overweight rating on Annexon Biosciences (NASDAQ: ANNX).

Dex Genotek

TR | OpenAI - 4o

―

Sell

―

Reiterated

04/22/25

AI Generated ArticleAI Generated Article

Anupam Rama

J.P. Morgan

―

Buy

―

Reiterated

03/03/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Annexon Biosciences

1 Month

xxx

Success Rate

14/26 ratings generated profit

Average Return

-1.41%

reiterated a xxx

rating 14 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 53.85% of your transactions generating a profit, with an average return of -1.41% per trade.

3 Months

xxx

Success Rate

5/12 ratings generated profit

Average Return

+4.20%

reiterated a xxx

rating 15 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 41.67% of your transactions generating a profit, with an average return of +4.20% per trade.

1 Year

Derek ArchilaWells Fargo

Success Rate

3/14 ratings generated profit

Average Return

-14.25%

reiterated a buy rating 14 days ago

Copying Derek Archila's trades and holding each position for 1 Year would result in 21.43% of your transactions generating a profit, with an average return of -14.25% per trade.

2 Years

xxx

Success Rate

7/26 ratings generated profit

Average Return

-30.36%

reiterated a xxx

rating 14 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 26.92% of your transactions generating a profit, with an average return of -30.36% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ANNX Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ANNX has received 14 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ANNX average Analyst price target in the past 3 months is 11.60.

Each month's total comprises the sum of three months' worth of ratings.

ANNX Financial Forecast

ANNX Earnings Forecast

Next quarter’s earnings estimate for ANNX is -$0.34 with a range of -$0.35 to -$0.32. The previous quarter’s EPS was -$0.34. ANNX beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 32.71% of the time in the same period. In the last calendar year ANNX has Outperformed its overall industry.

No data currently available

ANNX Sales Forecast

Next quarter’s sales forecast for ANNX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. ANNX beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 44.14% of the time in the same period. In the last calendar year ANNX has Preformed in-line its overall industry.

ANNX Stock Forecast FAQ

What is ANNX’s average 12-month price target, according to analysts?

Based on analyst ratings, Annexon Biosciences, Inc.’s 12-month average price target is 11.60.

What is ANNX’s upside potential, based on the analysts’ average price target?

Annexon Biosciences, Inc. has 449.76% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ANNX a Buy, Sell or Hold?

Annexon Biosciences, Inc. has a consensus rating of Strong Buy which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.

What is Annexon Biosciences, Inc.’s price target?

The average price target for Annexon Biosciences, Inc. is 11.60. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $14.00 ,the lowest forecast is $9.00. The average price target represents 449.76% Increase from the current price of $2.11.

What do analysts say about Annexon Biosciences, Inc.?

Annexon Biosciences, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.

How can I buy shares of ANNX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Annexon Biosciences (ANNX) Stock Forecast & Price Target

ANNX Analyst Ratings

ANNX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Annexon Biosciences

ANNX Analyst Recommendation Trends

ANNX Financial Forecast

ANNX Earnings Forecast

ANNX Sales Forecast

ANNX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts